U.S. Genomics has pioneered commercial applications of single molecule DNA, RNA and protein analysis. The company's innovative technologies address high value unmet needs in bio-security, human diagnostics, and food and drug contaminant monitoring. Addressable segments of these markets where the company's technology offers compelling advantage approach $4.0 billion. 
   
U.S. Genomics' core genomic mapping technologies are capable of identifying and quantitating individual molecules of DNA, RNA and proteins from a complex sample. Large fragments of genomic DNA are extracted from complex samples utilizing a proprietary sample preparation technology. Universal reagent sets are used, and no target amplification or culture is required. DNA detection using these technologies provides genomic species and strain identification, while quantitation of RNAs and proteins can be used to track expression, all within a highly mutiplexable assay format. The core U.S. Genomics genomic mapping technologies are protected by 60 families of patents with priority dating to the company's foundation in 1997. The universal reagent sets used by the company avoid use of long sequence-specific probes and primers typically associated with PCR thereby enabling broad freedom to operate.

U.S. Genomics is pursuing its major market opportunities in partnership with market leaders in each application area. The company's key co-development partners include Northrop Gruman in the field of bio-security.

Founded in 1997 and based in Woburn, Massachusetts, U.S. Genomics has raised a total of $61 million from HealthCare Ventures, StillRiver Fund, CB Health Ventures, Fidelity Biosciences Group, Zero Stage Capital and private investors. In addition, the company has been awarded Phase I, II and III contracts totaling $39 million by the U.S. Department of Homeland Security Advanced Research Project Agency (HSARPA) and other U.S. Government agencies to develop a sophisticated biological sensor for biodefense applications.